<- Go Home
Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical macromolecule contract development manufacture organization (CDMO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solutions. In addition, the company is involved in development and drug product manufacturing; provision of pharmaceutical analysis and testing services; medical research and development; manufacturing, sale, and development of medicine raw materials and relevant products; sale of drug products; pharmaceuticals and chemical manufacturing; wholesaling and retailing of drugs; sale, import and export trade; information technology; technology development; and research and experimental development activities. The company was founded in 1998 and is headquartered in Tianjin, China.
Market Cap
CNY 26.9B
Volume
4.7M
Cash and Equivalents
CNY 5.8B
EBITDA
CNY 1.1B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CNY 2.4B
Profit Margin
41.55%
52 Week High
CNY 94.28
52 Week Low
CNY 59.55
Dividend
1.42%
Price / Book Value
1.62
Price / Earnings
28.89
Price / Tangible Book Value
1.68
Enterprise Value
CNY 19.6B
Enterprise Value / EBITDA
17.60
Operating Income
CNY 618.7M
Return on Equity
5.44%
Return on Assets
1.98
Cash and Short Term Investments
CNY 7.6B
Debt
CNY 324.8M
Equity
CNY 16.9B
Revenue
CNY 5.8B
Unlevered FCF
-CNY 425.2M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium